Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model

This publication has 51 references indexed in Scilit:

• Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus
  Cancer Gene Therapy, 2002
• Development of a Syngenic Murine B16 Cell Line-Derived Melanoma Susceptible to Destruction by Neuroattenuated HSV-1
  Molecular Therapy, 2001
• Combined Therapy with Chemotherapeutic Agents and Herpes Simplex Virus Type 1 ICP34.5 Mutant (HSV-1716) in Human Non-Small Cell Lung Cancer
  Human Gene Therapy, 1999
• Cancer statistics, 1999
  CA: A Cancer Journal for Clinicians, 1999
• Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1
  Human Gene Therapy, 1998
• Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer
  Gene Therapy, 1998
• Infected Cell Protein (ICP)47 Enhances Herpes Simplex Virus Neurovirulence by Blocking the CD8+ T Cell Response
  The Journal of Experimental Medicine, 1998
• A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain Tumors
  Human Gene Therapy, 1997
• Analysis of prognostic factors for patients with single brain metastasis treated with stereotactic radiosurgery
  Radiation Oncology Investigations, 1997
• Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models.
  Journal of Clinical Investigation, 1993